AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|
13.5 C
New York
Tuesday, October 20, 2026

Tag: treatment

Edible Garden Delivers Strong Performance Across Core and Key Segments, Driven by Strategic Portfolio Transformation

 Company exits low-margin product lines, invests in higher-margin, innovative CEA-informed, better-for-you shelf-stable products, and expands global reach

HLS Therapeutics Announces Q2 2025 Financial Results

Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

Oil & Gas Market Size to Surpass USD 8.79 Trillion by 2034

According to Towards Chemical and Materials, the global Oil & Gas market size was estimated at USD 6.10 Trillion in 2024 and is expected to surpass around USD 8.79 Trillion by 2034, growing at a compound annual growth rate (CAGR) of 3.72% over the forecast period from 2025 to 2034.
According to Towards Chemical and Materials, the global Oil & Gas market size was estimated at USD 6.10 Trillion in 2024 and is expected to surpass around USD 8.79 Trillion by 2034, growing at a compound annual growth rate (CAGR) of 3.72% over the forecast period from 2025 to 2034.

Zeekr Group Reports Second Quarter 2025 Unaudited Financial Results

HANGZHOU, China, Aug. 14, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new...

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to...

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

NativePath Liposomal Vitamin C: Urgent 2025 Consumer Warning on Why Most Vitamin C Pills May Fail — And the 3-in-1 Formula Positioned for Better...

Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.
Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.

Vertigenics – The Natural Vertigo Breakthrough Driving 2025 Interest in Balance and Brain Support Formulas

Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025
Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025

LungExpand Pro Gains 2025 Spotlight as Plant-Based Daily Support Formula Amid Rising Public Interest in Breathing Comfort and Respiratory Wellness

Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.
Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

Neuro Sharp Gains Recognition in 2025 as Your Ultimate Brain Enhancement Formula

Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support
Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment